Daiichi Sankyo Co. Ltd. must pay Seagen Inc. $41.8 million because Enhertu, a breast-cancer treatment Daiichi markets with AstraZeneca Pharmaceuticals LP, infringes a Seagen patent for technology that delivers chemotherapy drugs directly to cancer cells, an East Texas jury found.
A jury in the U.S. District Court for the Eastern District of Texas found Daiichi does infringe U.S. Patent No. 10,808,039. Jurors also rejected arguments that the patent is invalid because it doesn’t cover a novel invention.
The trial started Monday in Marshall, Texas.
“Daiichi Sankyo disagrees with the jury verdict, is committed to defending its rights, and will explore ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.